Anixa Biosciences Inc (ANIX) Stock Price, Quote & News

Company Profile

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs include the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company's vaccine programs include the development of a vaccine against breast cancer, initially focused on triple negative breast cancer (TNBC), the...

Industry: Biotechnology

Sector: Healthcare

Phone: 408 708 9808

Website: www.anixa.com

Address:

3150 Almaden Expressway, Suite 250, San Jose, United States

emaccheese Oct. 3 at 8:37 PM

$ANIX

0 · Reply

larry88 Oct. 3 at 4:59 PM

$ANIX Jump in before the close today!

0 · Reply

stockobserver51 Oct. 1 at 5:41 AM

$ANIX It's slowly but surely heading towards $2.

2 · Reply

NVDAMillionaire Sep. 29 at 9:21 PM

$ANIX Excellent article that nails exactly where ANIX stands right now. So if you want to update your ANIX knowledge or get acquainted with ANIX, this is a must read. https://beyondspx.com/quote/ANIX/analysis/anixa-biosciences-unlocking-oncology-s-future-with-a-targeted-pipeline-and-strategic-collaborations-nasdaq-anix

0 · Reply

justiceforb_85 Sep. 24 at 11:00 PM

$ANIX this should fly with breast cancer vaccine update. Ovarian cancer CER-T update will be a bonus.

0 · Reply

highnihilism Sep. 24 at 1:23 PM

Market cap ≤ $500M (Unusual Volume, Biotech) $ADVM Adverum Biotechnologies $ANIX Anixa Biosciences $BNOX Bionomics $CANF Can-Fite BioPharma $ONCS OncoSec Medical

0 · Reply

Scientwist Sep. 24 at 5:50 AM

$ANIX December is gunna be big!

0 · Reply

stockobserver51 Sep. 23 at 4:10 PM

$ANIX And once again, just a gambler's candle, driving things up and cashing in on meaningless news. And on December 11th, this will happen again for the umpteenth time, and it will take years before FDA approval is granted. Phase 2 is scheduled to begin in 2026, but the exact date hasn't been announced, perhaps not until December. Anyone with that much time and the potential to reward themselves with millions won't attract investors to this stock. $2 at the end of the year.

3 · Reply

jshdn Sep. 23 at 4:40 AM

$ANIX two things. Number one ... what is the data that we are waiting for? I thought we already know the data on the percentage of people who developed a reaction positively to the vaccine at seventy percent. Or is this much more granular data about the combination with keyTruda and other information? I realize this has been talked about a million times but I am still curious... Wouldn't a big pharma want to take a chance on buying this now and not wait for later when it is potentially 20 times more expensive? Yes I realize we don't know if it works a hundred percent but perhaps a big pharma with all of its resources and knowledge has an inkling whether it's gonna work or not... or no?

1 · Reply

Doozio Sep. 22 at 11:38 PM

$ANIX 🐒🍌🧠⏰♾️

0 · Reply

Cleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium

Sep 8, 2025, 8:00 AM EDT - 26 days ago

Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival

Sep 2, 2025, 8:54 AM EDT - 4 weeks ago

Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 25, 2025, 9:13 AM EDT - 5 weeks ago

Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 20, 2025, 8:37 AM EDT - 6 weeks ago

Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology

Aug 18, 2025, 9:00 AM EDT - 6 weeks ago

Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial

Aug 12, 2025, 8:05 AM EDT - 7 weeks ago

Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology

Aug 8, 2025, 9:15 AM EDT - 2 months ago

Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference

Aug 4, 2025, 8:45 AM EDT - 2 months ago

Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial

Jul 30, 2025, 8:15 AM EDT - 2 months ago

Anixa Biosciences Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Covering Breast Cancer Vaccine Technology

Jul 24, 2025, 8:00 AM EDT - 2 months ago

Anixa Biosciences Awarded New U.S. Patent Extending Breast Cancer Vaccine IP Protection into 2040s

Jul 15, 2025, 3:49 PM EDT - 2 months ago

Anixa Biosciences: Oncology Platform With Asymmetric Upside

Jul 9, 2025, 8:00 AM EDT - 3 months ago

Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology

Jun 23, 2025, 8:00 AM EDT - 3 months ago

Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial

Jun 20, 2025, 7:30 AM EDT - 3 months ago

Anixa Biosciences to Host an Investor Webcast on June 26, 2025

Jun 10, 2025, 7:00 AM EDT - 4 months ago

Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage

Jun 9, 2025, 8:00 AM EDT - 4 months ago

Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the ESMO Gynaecological Cancers Congress 2025

Jun 3, 2025, 7:25 AM EDT - 4 months ago

Anixa Biosciences' Breast Cancer Vaccine Featured in NewsNation Interview

Jun 2, 2025, 7:00 AM EDT - 4 months ago

Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine

May 19, 2025, 8:00 AM EDT - 4 months ago

Anixa Biosciences CEO Provides Letter to Shareholders Outlining Significant Progress and Advancement Towards Potentially Transformative Milestones

May 12, 2025, 8:00 AM EDT - 5 months ago

Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 30, 2025, 8:00 AM EDT - 5 months ago

Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th

Apr 14, 2025, 8:00 AM EDT - 6 months ago

Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio

Apr 9, 2025, 8:00 AM EDT - 6 months ago

Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology

Apr 1, 2025, 8:00 AM EDT - 6 months ago

Anixa Biosciences to Present at the Jones Las Vegas Healthcare and Technology Innovation Conference on April 9th

Mar 25, 2025, 8:00 AM EDT - 6 months ago

Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines

Mar 24, 2025, 8:00 AM EDT - 6 months ago

Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine

Mar 17, 2025, 8:00 AM EDT - 7 months ago

Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th

Mar 10, 2025, 8:30 AM EDT - 7 months ago

Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties

Mar 3, 2025, 8:00 AM EST - 7 months ago

Anixa Biosciences Announces Chief Development Officer Dr. Pam Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19th

Feb 26, 2025, 8:00 AM EST - 7 months ago

Anixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial

Feb 25, 2025, 7:30 AM EST - 7 months ago

Anixa Biosciences' Breast Cancer Vaccine was Featured on Fox News' "America Reports"

Feb 24, 2025, 8:00 AM EST - 7 months ago

Anixa Biosciences Featured in Breaking Cancer News Article on Novel CAR-T Therapy for Ovarian Cancer

Feb 18, 2025, 8:00 AM EST - 8 months ago

Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial

Feb 14, 2025, 7:00 AM EST - 8 months ago

Anixa Biosciences Chairman and CEO Discusses Pioneering CAR-T Cell Therapy and Breast Cancer Vaccine in Alpha Wolf Trading Interview

Feb 11, 2025, 8:30 AM EST - 8 months ago

Anixa Biosciences to Present at the 18th Annual European Life Sciences CEO Forum

Feb 4, 2025, 8:30 AM EST - 8 months ago

Anixa Biosciences' Chairman & CEO Dr. Amit Kumar Featured on CW39's H-Town Live to Discuss the Future of Breast Cancer Prevention

Jan 21, 2025, 8:30 AM EST - 9 months ago

Anixa Biosciences CEO Provides Letter to Shareholders

Dec 4, 2024, 8:30 AM EST - 10 months ago

Anixa Biosciences to Present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on December 10

Nov 22, 2024, 8:15 AM EST - 11 months ago

Anixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset

Nov 18, 2024, 8:20 AM EST - 11 months ago

Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial

Nov 8, 2024, 1:17 PM EST - 11 months ago

Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 6, 2024, 8:30 AM EST - 11 months ago

Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 31, 2024, 8:15 AM EDT - 1 year ago

Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024

Oct 28, 2024, 8:30 AM EDT - 1 year ago

Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 15, 2024, 9:00 AM EDT - 1 year ago

Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial

Oct 7, 2024, 8:30 AM EDT - 1 year ago

Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development

Sep 30, 2024, 8:30 AM EDT - 1 year ago

Anixa Biosciences Announces Submission of Protocol Amendment for CAR-T Trial

Sep 24, 2024, 8:30 AM EDT - 1 year ago

Anixa Biosciences Unveils Phase 2 Study Plan for Breast Cancer Vaccine

Sep 18, 2024, 8:30 AM EDT - 1 year ago

Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Ovarian Cancer Research Alliance's International Gynecologic Cancer Conference

emaccheese Oct. 3 at 8:37 PM

$ANIX

0 · Reply

larry88 Oct. 3 at 4:59 PM

$ANIX Jump in before the close today!

0 · Reply

stockobserver51 Oct. 1 at 5:41 AM

$ANIX It's slowly but surely heading towards $2.

2 · Reply

NVDAMillionaire Sep. 29 at 9:21 PM

0 · Reply

justiceforb_85 Sep. 24 at 11:00 PM

$ANIX this should fly with breast cancer vaccine update. Ovarian cancer CER-T update will be a bonus.

0 · Reply

highnihilism Sep. 24 at 1:23 PM

Market cap ≤ $500M (Unusual Volume, Biotech) $ADVM Adverum Biotechnologies $ANIX Anixa Biosciences $BNOX Bionomics $CANF Can-Fite BioPharma $ONCS OncoSec Medical

0 · Reply

Scientwist Sep. 24 at 5:50 AM

$ANIX December is gunna be big!

0 · Reply

stockobserver51 Sep. 23 at 4:10 PM

3 · Reply

jshdn Sep. 23 at 4:40 AM

1 · Reply

Doozio Sep. 22 at 11:38 PM

$ANIX 🐒🍌🧠⏰♾️

0 · Reply

justiceforb_85 Sep. 22 at 11:00 PM

$ANIX looking forward to updates in ovarian cancer and breast cancer vaccine.

0 · Reply

bioinvestorrr Sep. 22 at 5:47 PM

$ANIX still under the radar imo

0 · Reply

JarvisFlow Sep. 22 at 2:07 PM

D. Boral Capital has updated their rating for Anixa Biosciences ( $ANIX ) to Buy with a price target of 10.

0 · Reply

bioinvestorrr Sep. 22 at 12:37 PM

$ANIX SAN JOSE, Calif., Sept. 22, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that final results from the Phase 1 clinical trial of its breast cancer vaccine will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) on Thursday, December 11, 2025. "We are very encouraged by the data generated in this human clinical trial, which continues to exceed our expectations," stated Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "This vaccine builds on decades of pioneering preclinical work led by the late Vincent Tuohy, Ph.D. and his team at Cleveland Clinic. His visionary research, has brought us to this pivotal moment—one that has the potential to transform the future of breast cancer prevention and treatment."

0 · Reply

bioinvestorrr Sep. 22 at 12:35 PM

$ANIX let the run up begin

0 · Reply

Kher33 Sep. 22 at 12:10 PM

$ANIX https://ir.anixa.com/press-releases/detail/1098

0 · Reply

GMExAPE Sep. 17 at 9:22 PM

RMFC stock has 5X potential, shorts at zero borrow and the 3m float is locked. Very undervalued here. - No dilution - Catalysts coming - Just reported record financials and added a new store a few weeks ago. $CATX $FTEK $ANIX $LIVE $LYEL www

0 · Reply

Rideabull Sep. 17 at 7:06 PM

$ANIX As expected...out of steam.

0 · Reply

Scientwist Sep. 17 at 7:58 AM

$ANIX December will be very interesting..

0 · Reply

alsworthg Sep. 16 at 12:28 PM

$ANIX LFG!!!!

0 · Reply

BigSqueezeComing Sep. 16 at 2:42 AM

$ANIX Slow climber today. My watchlist for tomorrow.

0 · Reply

bioinvestorrr Sep. 15 at 7:57 PM

$ANIX no joke have been in this stock for 4 years never seen it run like this off no news lol

1 · Reply

Market Cap	107.64M
Revenue (ttm)	0.00
Net Income (ttm)	-12.55M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	67,400
Avg Vol	101,732
Day's Range	N/A - N/A
Shares Out	32.92M
Stochastic %K	19%
Beta	0.69
Analysts	Strong Sell
Price Target	$9.00